# Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

> **NCT03822468** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 376 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Anastrozole
- **DRUG:** Letrozole
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT03822468
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-11
- **Primary completion:** 2021-06-11
- **Final completion:** 2024-08-30
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822468, "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03822468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*